Comparing Voyager Therapeutics (NASDAQ:VYGR) & BIONDVAX PHARMA/S (NASDAQ:BVXV)

Voyager Therapeutics (NASDAQ:VYGR) and BIONDVAX PHARMA/S (NASDAQ:BVXV) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and price targets for Voyager Therapeutics and BIONDVAX PHARMA/S, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Voyager Therapeutics 0 2 6 0 2.75
BIONDVAX PHARMA/S 0 0 0 0 N/A

Voyager Therapeutics currently has a consensus target price of $29.17, suggesting a potential upside of 104.82%. Given Voyager Therapeutics’ higher possible upside, equities analysts clearly believe Voyager Therapeutics is more favorable than BIONDVAX PHARMA/S.

Profitability

This table compares Voyager Therapeutics and BIONDVAX PHARMA/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Voyager Therapeutics -72.64% -57.32% -15.83%
BIONDVAX PHARMA/S N/A N/A -102.90%

Volatility and Risk

Voyager Therapeutics has a beta of 2.58, indicating that its share price is 158% more volatile than the S&P 500. Comparatively, BIONDVAX PHARMA/S has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500.

Valuation and Earnings

This table compares Voyager Therapeutics and BIONDVAX PHARMA/S’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Voyager Therapeutics $7.62 million 69.28 -$88.29 million ($2.75) -5.18
BIONDVAX PHARMA/S N/A N/A -$23.41 million ($3.60) -1.62

BIONDVAX PHARMA/S has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than BIONDVAX PHARMA/S, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

78.6% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 6.2% of BIONDVAX PHARMA/S shares are owned by institutional investors. 22.9% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 6.0% of BIONDVAX PHARMA/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Voyager Therapeutics beats BIONDVAX PHARMA/S on 8 of the 12 factors compared between the two stocks.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD101 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and VY-NAV01 for severe chronic pain. The company has strategic collaboration agreements with AbbVie Inc.; Sanofi Genzyme; the University of Massachusetts; and MRI Interventions, Inc., as well as collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

BIONDVAX PHARMA/S Company Profile

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Ness Ziona, Israel.

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.